QuantiGene Plex Assays quantigene

 

Figure 1. Branched DNA signal amplification on Luminex beads. Click on the image to learn more about the Luminex xMAP platform. Courtesy of eBiosciences.

Welcome to the new era of quantitative targeted gene and microRNA expression profiling using eBiosciences’ QuantiGene Plex assays. The QuantiGene system efficiently measures up to 80 RNA targets per sample directly from a variety of sample types, effectively bypassing RNA isolation, with no cross-reactivity. By utilizing branched DNA (bDNA) signal amplification technology on Luminex xMAP beads, these assays can distinguish percentage differences in RNA copy number with a low coefficient of variation, less than 15% for the entire process. Click here for more information on the Luminex xMAP technology.

The QuantiGene workflow has also removed the reverse transcription and PCR amplification steps which eliminates any associated artifacts and enables reduced sample consumption. These assays can also directly quantify ncRNA, fusion transcripts, and DNA copy number variations. QuantiGene assays are utilized to advance research in numerous disease areas, including multiple focus areas in oncology; gastrointestinal stromal tumors, lung, pancreatic, breast, colorectal, and prostrate cancers1-8.

ORB provides cost-effective customizable QuantiGene assays to rapidly characterize mRNA and microRNA targets as standalone projects or confirmation studies following broader interrogation strategies such as RNA sequencing and gene expression and microRNA microarray. To support biomarker discovery projects, ORB’s predictive modeling analyses can be used to select the best performing targets for validation using QuantiGene assays.  Follow the links below to learn more about related applications.


Sample Types Suitable for QuantiGene Assays

  • Whole blood
  • PAXgene samples
  • Tempus blood
  • Blood spots
  • Fresh/frozen tissue (plant & animal)
  • H&E stained FFPE
  • Unstained FFPE
  • Urine
  • Cultured cells
  • Bacteria
  • Purified RNA & DNA


Contact us for sample-specific starting input requirements for the QuantiGene assays and the appropriate sample submission checklist for your study.

Highlights of QuantiGene Assays

  • Ultra-low starting input requirements for all sample types, including biofluid
  • Maximum accuracy and precision achieved from the removal of sample purification steps, cDNA synthesis, and PCR amplification
  • Assays available for many species, shown below:
  • Elimination of blood fractionation and globin RNA reduction
  • Multiple probes per target provide ultimate specificity
  • Customization of up to 55 targets per assay
  • Human
  • Mouse
  • Rat
  • Pig
  • Dog
  • Dog
  • Monkey
  • Rabbit
  • Chinese hamster
  • Syrian hamster
  • Nematode
  • Guinea pig
  • Fly
  • Horse
  • Zebra fish
  • Cow
  • Atlantic salmon
  • Chicken
  • House sparrow
  • Woodchuck
  • HPV
  • Herpes
  • Vibrio cholarae
  • Vibrio harveyl

Contact Us to learn how QuantiGene assays can advance your targeted nucleic acid research!


References

  1. Li, C. F., et al. "Transcriptomic reappraisal identifies MGLL overexpression as an unfavorable prognosticator in primary gastrointestinal stromal tumors." Ranking: http://gateway. webofknowledge. com/gateway/Gateway. cgi? GWVersion= 2&SrcAuth= NHRI&SrcApp= NHRI_IR&KeyISSN= 1949- 2553&DestApp= IC2JCR (2016).
  2. Mao, Jenny T., et al. "Grape Seed Procyanidin Extract Mediates Antineoplastic Effects against Lung Cancer via Modulations of Prostacyclin and 15-HETE Eicosanoid Pathways." Cancer Prevention Research 9.12 925-932: (2016).
  3. Yu M., et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 487 (7408): 510-3 (2012).
  4. Ting T., et al. Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science 331(6017):593-6 (2011).
  5. Kang Y. G., et al. Prognostic significance of S100A4 mRNA and protein expression in colorectal cancer. Journal of Surgical Oncology doi: 10.1002/ jso.22070 (2011).
  6. Chae B. J., et al. Measurement of ER and PR status in breast cancer using the QuantiGene2.0 assay. Pathology 43(3):248-53 (2011).
  7. Furusato B., et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer and Prostatic Diseases 13(3):228-37 (2010).
  8. Lu B., et al. Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA. Urology 74(5):1156- 61 (2009).